i left my bpc 157 out overnight FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid the data gaps, the whole case. Panel overruled them how long should i take

Risk-benefit analysis should consider the severity and impact of the condition being treated, failure or limitations of conventional therapies, individual patient risk factors particularly for malignancy, and patient preferences regarding experimental treatments

Results vary depending on the condition being treated and individual factors

Flares can occur on the inner elbows during one episode and behind the knees or on the wrists during another

This involves comprehensive preclinical testing, multiple phases of human clinical trials, and stringent manufacturing quality control

Tolerance development : Effects diminish over time, requiring higher doses